» Articles » PMID: 37097406

An Evaluation of the Effect of Lithium on Taxane-induced Neuropathy

Overview
Specialties Critical Care
Oncology
Date 2023 Apr 25
PMID 37097406
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: No medications are known to protect against chemotherapy-induced peripheral neuropathy (CIPN). Pre-clinical models suggest that lithium may lessen taxane-induced neuropathy. Our aim was to use clinical data to assess whether concurrent lithium usage decreased the frequency or severity of CIPN in patients receiving taxane chemotherapy.

Methods: A retrospective analysis was performed using the electronic health record at Mayo Clinic to identify all patients prescribed concurrent lithium and paclitaxel. Four controls were matched to each case based on clinical variables. Neuropathy severity was graded from available patient and clinician reports. Rates of any neuropathy, dose reduction for CIPN, and treatment discontinuation for CIPN were compared. Conditional regression analysis was performed with propensity score matching.

Results: Six patients, receiving concurrent lithium and paclitaxel, were included in the analysis, and compared to 24 control cases. A similar number of paclitaxel cycles were administered to both groups. Any neuropathy was experienced by 33% (2/6) of patients receiving lithium and 38% (9/24) patients who did not receive lithium (p = 1.000). There was no difference in neuropathy severity (p = 0.8565), rate of chemotherapy dose reduction (17% vs. 17%, p = 1.000), or treatment discontinuation (17% vs 4%, p = 0.3655) for CIPN. In the propensity score analysis, the odds ratio for developing any neuropathy was 0.63 (95% confidence interval, 0.06 to 6.96, p = 0.7079).

Conclusions: Lithium does not appear to significantly lessen the risk of neuropathy for patients receiving paclitaxel.

Implications For Cancer Survivors: Targeted approaches for preventing CIPN are desperately needed. Despite sound scientific rationale, the current study did not identify neuroprotective properties of lithium.

Citing Articles

Response to Kochan et al., 2023.

Ehrlich B, Vahdat L, DeCillis A, Seidman A Support Care Cancer. 2023; 31(8):486.

PMID: 37480366 DOI: 10.1007/s00520-023-07950-w.

References
1.
Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L . Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2020; 29(2):833-840. PMC: 7714711. DOI: 10.1007/s00520-020-05543-5. View

2.
Loprinzi C, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz D . Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020; 38(28):3325-3348. DOI: 10.1200/JCO.20.01399. View

3.
Fernyhough P, Calcutt N . Abnormal calcium homeostasis in peripheral neuropathies. Cell Calcium. 2009; 47(2):130-9. PMC: 2834846. DOI: 10.1016/j.ceca.2009.11.008. View

4.
Laforgia M, Laface C, Calabro C, Ferraiuolo S, Ungaro V, Tricarico D . Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms. Int J Mol Sci. 2021; 22(4). PMC: 7922628. DOI: 10.3390/ijms22041980. View

5.
Wang M, Davis A, Culver D, Wang Q, Powers J, Glass J . Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain. 2004; 127(Pt 3):671-9. DOI: 10.1093/brain/awh078. View